Success Metrics

Clinical Success Rate
60.0%

Based on 3 completed trials

Completion Rate
60%(3/5)
Active Trials
0(0%)
Results Posted
67%(2 trials)
Terminated
2(40%)

Phase Distribution

Ph phase_4
1
20%
Ph phase_1
4
80%

Phase Distribution

4

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
4(80.0%)
Phase 4Post-market surveillance
1(20.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

60.0%

3 of 5 finished

Non-Completion Rate

40.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(3)
Terminated(2)

Detailed Status

Completed3
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
60.0%
Most Advanced
Phase 4

Trials by Phase

Phase 14 (80.0%)
Phase 41 (20.0%)

Trials by Status

terminated240%
completed360%

Recent Activity

0 active trials
Showing 5 of 5
completedphase_4

Study Of MK-0752 In Combination With Tamoxifen Or Letrozole to Treat Early Stage Breast Cancer

NCT00756717
terminatedphase_1

A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)

NCT01243762
completedphase_1

A Clinical Study to Determine Biomarkers of Response to a Gamma Secretase Inhibitor

NCT00803894
completedphase_1

Safety and Tolerability of Different Dose Combinations of Ridaforolimus With MK-2206 or MK-0752 for Participants With Advanced Cancer (MK-8669-049)

NCT01295632
terminatedphase_1

MK0752 in Treating Young Patients With Recurrent or Refractory CNS Cancer

NCT00572182

Clinical Trials (5)

Showing 5 of 5 trials
NCT00756717Phase 4

Study Of MK-0752 In Combination With Tamoxifen Or Letrozole to Treat Early Stage Breast Cancer

Completed
NCT01243762Phase 1

A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)

Terminated
NCT00803894Phase 1

A Clinical Study to Determine Biomarkers of Response to a Gamma Secretase Inhibitor

Completed
NCT01295632Phase 1

Safety and Tolerability of Different Dose Combinations of Ridaforolimus With MK-2206 or MK-0752 for Participants With Advanced Cancer (MK-8669-049)

Completed
NCT00572182Phase 1

MK0752 in Treating Young Patients With Recurrent or Refractory CNS Cancer

Terminated

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5